MedTrace Logo

Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy

NCT06329700 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2024-03-26

No results posted yet for this study

Summary

Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.

Conditions

  • Colorectal Cancer Stage IV

Interventions

PROCEDURE

Hepatectomy

Surgical removal of a part of the liver

Sponsors & Collaborators

  • Azienda Ospedaliero Universitaria Maggiore della Carita

    lead OTHER

Principal Investigators

  • Matteo Donadon, MD, PhD · University of Eastern Piedmont

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-01
Primary Completion
2019-12-31
Completion
2022-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06329700 on ClinicalTrials.gov